Cargando…
Evidence on the cost of breast cancer drugs is required for rational decision making
BACKGROUND: For rational decision making, assessing the cost-effectiveness and budget impact of new drugs and comparing the costs of drugs already on the market is required. In addition to value frameworks, such as the American Society of Clinical Oncology Value Framework and the European Society of...
Autores principales: | Berghuis, Anne Margreet Sofie, Koffijberg, Hendrik, Terstappen, Leonardus Wendelinus Mathias Marie, Sleijfer, Stefan, IJzerman, Maarten Joost |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931813/ https://www.ncbi.nlm.nih.gov/pubmed/29743945 http://dx.doi.org/10.3332/ecancer.2018.825 |
Ejemplares similares
-
Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material
por: Berghuis, A. M. Sofie, et al.
Publicado: (2019) -
Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility
por: Berghuis, A. M. Sofie, et al.
Publicado: (2017) -
HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer
por: Nanou, Afroditi, et al.
Publicado: (2020) -
Health Economic Evidence of Point-of-Care Testing: A Systematic Review
por: Lingervelder, Deon, et al.
Publicado: (2021) -
EpCAM(high) and EpCAM(low) circulating tumor cells in metastatic prostate and breast cancer patients
por: de Wit, Sanne, et al.
Publicado: (2018)